Trial · NCT04984876
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ligelizumab 240 mg | 47 | |
| Overall Study | STARTED | Ligelizumab 120 mg | 51 | |
| Overall Study | STARTED | Placebo 8 Weeks and Ligelizumab 240 mg | 46 | |
| Overall Study | STARTED | Placebo 8 Weeks and Ligelizumab 120 mg | 44 | |
| Overall Study | STARTED | Placebo 16 Weeks and Ligelizumab 240 mg | 11 | |
| Overall Study | STARTED | Placebo 16 Weeks and Ligelizumab 120 mg | 12 | |
| Overall Study | Randomized Analysis Set (RAS) | Ligelizumab 240 mg | 47 | |
| Overall Study | Randomized Analysis Set (RAS) | Ligelizumab 120 mg | 51 | |
| Overall Study | Randomized Analysis Set (RAS) | Placebo 8 Weeks and Ligelizumab 240 mg | 46 | |
| Overall Study | Randomized Analysis Set (RAS) | Placebo 8 Weeks and Ligelizumab 120 mg | 44 | |
| Overall Study | Randomized Analysis Set (RAS) | Placebo 16 Weeks and Ligelizumab 240 mg | 11 | |
| Overall Study | Randomized Analysis Set (RAS) | Placebo 16 Weeks and Ligelizumab 120 mg | 12 | |
| Overall Study | Full Analysis Set (FAS) | Ligelizumab 240 mg | 47 | |
| Overall Study | Full Analysis Set (FAS) | Ligelizumab 120 mg | 51 | |
| Overall Study | Full Analysis Set (FAS) | Placebo 8 Weeks and Ligelizumab 240 mg | 46 | |
| Overall Study | Full Analysis Set (FAS) | Placebo 8 Weeks and Ligelizumab 120 mg | 44 | |
| Overall Study | Full Analysis Set (FAS) | Placebo 16 Weeks and Ligelizumab 240 mg | 11 | |
| Overall Study | Full Analysis Set (FAS) | Placebo 16 Weeks and Ligelizumab 120 mg | 12 | |
| Overall Study | Safety Set (SAF) | Ligelizumab 240 mg | 47 | |
| Overall Study | Safety Set (SAF) | Ligelizumab 120 mg | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04984876/flow